| Mr Christopher Charles Gillis, MD | |
|
745 Hope Rd 2nd Floor, Eatontown, NJ 07724 | |
| (732) 222-8866 | |
| (732) 544-2068 |
| Full Name | Mr Christopher Charles Gillis |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 16 Years |
| Location | 745 Hope Rd 2nd Floor, Eatontown, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669891180 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Monmouth Medical Center | Long branch, NJ | Hospital |
| Riverview Medical Center | Red bank, NJ | Hospital |
| Bayshore Medical Center | Holmdel, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Neurosurgical Associates Of New Jersey, P.c. | 2961405055 | 32 |
News Archive
Far more breast cancer patients are choosing to undergo mastectomy, including removal of both breasts, instead of choosing breast conservation surgery even when they have early stage disease that is confined to one breast, a Vanderbilt study shows. In the past decade, there have also been marked trends toward higher proportions of women opting for breast reconstruction.
Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.
A rule issued today by the Food and Drug Administration underscores the historical progress made towards fighting the nation's number one cause of preventable death: tobacco-related disease.
› Verified 7 days ago
| Entity Name | Neurosurgical Associates Of New Jersey, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992753594 PECOS PAC ID: 2961405055 Enrollment ID: O20060810000008 |
News Archive
Far more breast cancer patients are choosing to undergo mastectomy, including removal of both breasts, instead of choosing breast conservation surgery even when they have early stage disease that is confined to one breast, a Vanderbilt study shows. In the past decade, there have also been marked trends toward higher proportions of women opting for breast reconstruction.
Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.
A rule issued today by the Food and Drug Administration underscores the historical progress made towards fighting the nation's number one cause of preventable death: tobacco-related disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Christopher Charles Gillis, MD 745 Hope Rd 2nd Floor, Eatontown, NJ 07724 Ph: (732) 222-8866 | Mr Christopher Charles Gillis, MD 745 Hope Rd 2nd Floor, Eatontown, NJ 07724 Ph: (732) 222-8866 |
News Archive
Far more breast cancer patients are choosing to undergo mastectomy, including removal of both breasts, instead of choosing breast conservation surgery even when they have early stage disease that is confined to one breast, a Vanderbilt study shows. In the past decade, there have also been marked trends toward higher proportions of women opting for breast reconstruction.
Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.
A rule issued today by the Food and Drug Administration underscores the historical progress made towards fighting the nation's number one cause of preventable death: tobacco-related disease.
› Verified 7 days ago
Dr. Ty James Olson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 745 Hope Road 2nd Floor, Eatontown, NJ 07724 Phone: 732-222-8866 Fax: 732-544-2068 |